DEF 14A: Biofrontera Seeks Stockholder Approval to Increase Authorized Common Stock Amid Private Placement Obligations

Biofrontera Inc. is holding a special meeting to seek stockholder approval for increasing its authorized common stock from 15 million to 35 million shares, primarily to fulfill obligations related to a recent private placement and for future business needs.

Summary

• Biofrontera Inc. is convening a special meeting of stockholders on April 24, 2024, to vote on two proposals.
• The first proposal seeks to amend the company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 15,000,000 to 35,000,000.
• The second proposal requests approval to adjourn the Special Meeting to a later date if necessary to solicit additional proxies for the Share Increase Proposal.
• The Board of Directors unanimously recommends voting FOR both proposals.
• The primary reason for the Share Increase Proposal is to meet obligations arising from a private placement completed on February 19, 2024, where the company issued Preferred Stock and warrants.
• The company needs to reserve additional shares of Common Stock to cover potential conversions of Series B-3 Convertible Preferred Stock if warrant holders exercise their warrants.
• Based on the current conversion price of $0.7074 per share, an additional 11,309,019 shares of Common Stock would need to be reserved.
• If the Share Increase Proposal is not approved, Biofrontera may not receive up to $8 million in aggregate gross proceeds from the exercise of the Warrants.
• The Share Increase Amendment will not, by itself, have an immediate dilutive effect on our existing stockholders.
• The Board also seeks increased flexibility for future financing activities, stock dividends, acquisitions, and equity-based compensation.
• As of March 18, 2024, Biofrontera had 5,089,413 shares of Common Stock outstanding and 4,806 shares of Series B-1 Convertible Preferred Stock outstanding, representing 28,191 votes.
• The record date for determining stockholders eligible to vote at the Special Meeting was March 18, 2024.
• The company expects to file the Certificate of Amendment as soon as practicable after stockholder approval.
• The Share Increase Amendment will become effective upon the filing of the Certificate of Amendment with the Secretary of State of the State of Delaware.

Sentiment

Score: 7

Explanation: The document is primarily procedural, seeking approval for a standard corporate action. While there are potential benefits to approval, there are also risks associated with not approving the proposal. The sentiment is neutral to slightly positive.

Positives

• Approval of the Share Increase Proposal would allow Biofrontera to fulfill its obligations related to the private placement.
• The company would gain flexibility for future financing activities, stock dividends, acquisitions, and equity compensation.
• The Board believes that the proposed increase in authorized Common Stock will make sufficient shares available to fulfill the Company's obligations in the Private Placement and to provide the additional flexibility necessary to pursue our strategic objectives.

Negatives

• Failure to approve the Share Increase Proposal could prevent Biofrontera from receiving up to $8 million in gross proceeds from warrant exercises.
• The cost, prior notice requirements and delay involved in obtaining stockholder approval at the time that corporate action may be necessary or desirable could completely eliminate our ability to opportunistically capitalize on favorable market windows, which could delay or preclude our ability to advance our product candidate development and potential commercialization efforts.
• Future issuances of Common Stock or securities convertible into or exchangeable for Common Stock could have a dilutive effect on our earnings per share, book value per share and the voting power and interest of current stockholders.

Risks

• If the Share Increase Proposal is not approved, the company may not be able to raise future capital without first obtaining stockholder approval for an increase in the number of authorized shares of Common Stock.
• Future issuances of Common Stock or securities convertible into or exchangeable for Common Stock could have a dilutive effect on our earnings per share, book value per share and the voting power and interest of current stockholders.
• The availability of additional authorized shares for issuance could, under certain circumstances, discourage or make more difficult efforts to obtain control of our company.

Future Outlook

The company aims to gain flexibility for future financing activities, stock dividends, acquisitions, and equity compensation through the proposed increase in authorized shares.

Management Comments

• The Board of Directors unanimously recommends that you vote FOR Proposals No. 1 and No. 2.
• Our Board believes that it is in the best interest of the Company and our stockholders to be able to adjourn the Special Meeting to a later date or dates, if necessary, or appropriate to solicit additional proxies in respect of the approval of the Share Increase Proposal if there are insufficient votes to approve it at the time of the Special Meeting or in the absence of a quorum.

Industry Context

Many biotech companies seek to increase their authorized share count to provide flexibility for future financings, strategic partnerships, and employee compensation. This move is fairly standard in the industry, especially for companies that have recently completed private placements or are anticipating future capital needs.

Comparison to Industry Standards

• Increasing authorized shares is a common practice among publicly traded companies, especially in the biotech sector, to ensure flexibility for future capital raises and strategic initiatives.
• Comparable companies like Galectin Therapeutics and Cassava Sciences have also sought shareholder approval to increase their authorized share capital to fund ongoing clinical trials and potential commercialization efforts.
• The requested increase from 15 million to 35 million shares appears reasonable given Biofrontera's current obligations and future growth plans.

Stakeholder Impact

• Approval of the Share Increase Proposal could benefit shareholders by providing the company with greater financial flexibility.
• Failure to approve the proposal could limit the company's ability to raise capital and pursue strategic opportunities, potentially impacting shareholder value.
• The Share Increase Amendment is not intended to modify the rights of existing stockholders in any material respect.

Next Steps

• Stockholders to vote on the Share Increase Proposal and the Adjournment Proposal at the Special Meeting on April 24, 2024.
• If approved, the company will file the Certificate of Amendment with the Secretary of State of the State of Delaware.
• The company will reserve sufficient shares of Common Stock to cover the conversion of the Series B-3 Convertible Preferred Stock that could be issued upon exercise of the Warrants.

Key Dates

Keywords

authorized shares, common stock, proxy statement, Biofrontera, private placement, stockholder approval, warrants